Table 2.

Drug classes in highly active antiretroviral therapy that have been implicated as risk factors for bone mineral density

Drug type
Protease inhibitors
Nucleoside/nucleotide reverse transcriptase inhibitors
Non-nucleoside reverse transcriptase inhibitors